RE:I would like to see TH endorse NASHIf cancer results are really good, clearly good, then the stock price will sharply rise and they will be able to finance both programs. If cancer results are unambiguously good, the next financing deal will be much less dilutive. So I don't think they are waiting for cancer results to start the phase III on NASH. If cancer is a failure, they will only have NASH to spend on. That being said, they are clearly cautious with NASH. This phase III is based on assumptions, extrapolations from indirect data. In my opinion, it's at least part of the reason why this program is not valued like a standard NASH phase III program stemming from good phase II data and with a patented new molecule. In other words, this program is based on a lot of scientific knowledge and indirect data that all lead to think it will work. But good results in a proper phase II trial would give better assurance of a positive outcome. I still think that in the end it will work, but they take the gravel road to try to get there because they can skip phase I and phase II. But the market prefer drugs coming to phase III from the higway.
SPCEO1 wrote: If the cancer results are good, will they prefer to spend their money there over NASH?